As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 26, 2026 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2026.

The company has informed that the Board of Directors of the company in its meeting held on 28 June 2026 has approved agreements with M/s C2C Pharma Ltd., Dhaka, Bangladesh for contract manufacturing of some products on behalf of Square Pharmaceuticals PLC. to meet increased demand of existing products and to introduce new products. It is mentionable that DSE has requested the company to provide copy of the agreement; however, DSE is yet to receive the copy of the agreement.

(Continuation news of SQURPHARMA): Reasons for Deviation in EPS and NOCFPS: Last year, revenue growth was restrained due to socio-political factors. However, in current year, not only has the business recovered from that slowdown, but it has also experienced a strong upward momentum in revenue performance consequently, both EPS and NOCFPS have recorded notable and healthy growth. (end)

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2026 at 3:00 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.

Mr. Samuel S Chowdhury, Chairman of the Company, has further informed that he has completed his buying of 2,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 20.01.2026.

Mr. Tapan Chowdhury, Managing Director of the company, has further informed that he has completed his buying of 2,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 5.01.2026.

Mrs. Ratna Patra, one of the Directors of the Company, has further informed that she has completed her buying of 1,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 15.01.2026.

(Cont. News of SQURPHARMA): Reasons for deviations: Last year, revenue growth war restrained due to socio-political factors. However, in current year, not only has the business recovered from that slowdown, but it has also experienced a strong upward momentum in revenue performance. Consequently, both EPS and NOCFPS have recorded notable and healthy growth. (end)

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2026 at 3:00 PM to consider, among others, Un-Audited Financial Statements for the Second Quarter (Q2) period ended December 31, 2025.

The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2025 to the respective shareholders.